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Background: The presence of a patent foramen ovale (PFO) has been associated with an
increase incidence of cryptogenic stroke. Patients who have a PFO and an associated
thrombophilia may have an increased risk of cerebral ischemic events. Percutaneous PFO
closure could be a safe and effective alternative therapeutic approach for these patients.
Methods: Consecutive patients who underwent PFO closure at a large academic centre
were evaluated. All patients underwent hypercoagulation testing with functional assays
for homocysteine; proteins C and S; antithrombin III; factor II mutation; factor V-Leiden
mutation; lipoprotein (a); elevated levels of antiphospholipids; including lupus anticoag-
ulant (LAC), anticardiolipin (aCL). We compared the safety and efficacy of percutaneous
PFO closure in this group of patients versus the group of patients without a hypercoag-
ulable state.
Results: Of 728 consecutive patients with PFO undergoing percutaneous PFO closure, a
hypercoagulable state was found in 234 patients (32.1%). There were no significant
differences on baseline demographics or echocardiographic characteristics. There were no
differences on success rate and complication rate between both groups. Follow up was
available in 708 patients (97.3%). Median follow-up was 17 month. During follow-up
there were no differences in TIA/stroke incidence (0.4% in the group with coagulation
disorder and 0.6% in the non-hypercoagulable group, log rank test p 0.997).
Conclusions: Percutaneous PFO closure is safe and effective therapeutic approach for
patients with criptogenic stroke and an underlying hypercoagulable state.
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Background: Many patients with atrial fibrillation (AF) at high risk for thromboembolic
events are not candidates for long-term oral anticoagulation (OAC). The left atrial
appendage (LAA) is the major site of thrombus formation in non-valvular AF. We report
procedural results with 6 month follow-up for LAA occlusion with the AMPLATZER™
Cardiac Plug (ACP) (St. Jude Medical, Plymouth, MN).
Methods: A total of 197 patients underwent ACP implantation at one of 15 investigative
centers in Europe in 2009-2011. 183 patients have completed their 6 month follow up
visit. Study follow up requirements included echocardiographic assessment at baseline,
pre-discharge 1 and 6 months post implant as well as rigorous neurological exam after a
suspected stroke, TIA or systemic embolism.
Results: The majority of patients (57.9%) had a history of permanent AF, mean age was
74.20 9.0, mean CHADS2 score 2.6 1.3. Prior stroke or TIA was reported by 39.2%
of patients. Patients were indicated for ACP therapy due to bleeding risk on oral
anticoagulation (OAC) (79.8%), prior hemorrhage (8.9%) or prior stroke on Warfarin
(11.3%). Only 3.9% of patients were on active OAC prior to implant. The ACP device
was successfully implanted in 96.6% of patients with a closure rate of 99.5% at implant
and 98.9% at six months. Device/procedure related safety events included: 0 (0.0%)
periprocedural strokes, 3 (1.5%) serious pericardial effusions, 5 (2.4%) device related
thrombus, and 3 (1.5%) device embolizations. The stroke rate was 1.98% at 101 patient
years compared with a CHADS2 prediction of 5.6%.
Conclusions: Although warfarin has been shown to be effective for AF, many patients
with AF are contraindicated for it. The ACP device is a good alternative for these patients
based on the reported excellent implant success, LAA closure, and yields an acceptable
safety profile. The rate of adverse events compares favorably with other LAA closure
devices despite the high risk patients enrolled in the Study.
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Background: Surgical treatment of functional mitral regurgitation (FMR) in the setting
of heart failure has adequate short-term results however, late recurrence of mitral
regurgitation is frequent and associated with high mortality. Patients with dilated left
ventricles (LV) at baseline appear to be a higher risk for early mortality (17.9%) and
readmission (Braun et al., 2008). We sought to determine the outcomes of patients with
FMR and dilated ventricles treated with the MitraClip device.
Methods: Prospective data was collected on patients undergoing therapy with the
MitraClip at the Montreal Heart Institute and Cedars Sinai Medical Center. Echo data was
obtained pre- and post-procedure. Severity of MR was assessed echocardiographically in
accordance with ASE Guidelines. Procedural success was defined as residual MR grade
of 2	 or less. Dilated left ventricle was defined as a left ventricular end-diastolic
dimension (LVEDD) 65mm. Mortality and hospital re-admission data was obtained
from chart review and hospital administration databases.
Results: A total of 70 patients underwent transcatheter leaflet repair with the MitraClip
at both centers during the study period. Ten were identified as having a dilated left
ventricle and significant mitral regurgitation. Procedural success in this group of patients
was 80% (n8). In one patient, we were unable to grasp the leaflets and no clip was
deployed, the patient subsequently died 12 days later from progressive renal failure while
a second patient required mitral valve surgery for persistent severe MR. There were no
procedural complications.
Patient Age
LVEDD
(mm) EF (%)
MR pre-
MitraClip
MR post-
MitraClip Clinical Outcome
1 67 74 25 4 1
2 88 68 30 4 1
3 73 68 60 4 4 Unable to place
clip, died 12d
post-procedure
4 77 66 20 3 2
5 79 76 20 4 2
6 73 83 20 3 1
7 70 70 20 3 3 MVR Day #2 post-
procedure
8 64 68 25 3 2
9 82 75 20 3 1 At 6 month mod
MR, NYHA class I
no admission in
hospital
10 56 81 42 4 2 At one and half
years no
admission for
heart failure,
grade 2 MR NYHA
class I
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Conclusions: Experience with the MitraClip in patients with a dilated left ventricle
suggests that the procedure is safe and feasible in most patients. Mortality and heart
failure-related hospital rates are low. This therapy may be an alternative to surgery in this
high-risk group of patients.
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Background: Left ventricle (LV) remodeling after anterior wall myocardial infarction leads
to increased LV volumes, myocardial stress and ultimately congestive heart failure (CHF).
Treatment options are limited for these high morbidity and mortality risk population.
Methods: The study included 39 patients with ischemic CHF class II-IV (NYHA),
akinetic or dyskinetic wall abnormality, ejection fraction between 15 and 40% and no
revascularization options were enrolled in 14 U.S. and European sites. The device was
deployed into the left ventricle apex to partition off the damaged myocardium. Warfarin
and ASA treatment for 1-year post implant. All events were adjudicated and CT, EKG and
echo data were analyzed by independent core labs.
Results: End-diastolic volume was 127.5cc pre-procedure, 106.7cc at 6-month and
114.7cc at 2 years by echo (p0.74 6M vs 2Y). There were no strokes and worsening
CHF or death occurred in 32.9% (per Protocol n34) or 29.5% (treated pts, n31) of
patients at 2 years. Average NYHA class reduced from 2.6 to 1.9 with 87% of patients
reporting improvement in symptoms at 12 months. Adjudication of 3-year clinical events
will be completed in July 2012 and will be available for presentation.
Conclusions: Sustained 2-year improvement in symptoms and LV volume was observed
after PVR using the ParachuteTM device in patients with ischemic CHF and anterior LV
dilatation. Three-year clinical data will provide important insights into long-term safety of
this novel therapy.
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Background: Recent studies have raised major concerns about an increased risk of
cerebrovascular events (CVE) following transcatheter aortic valve implantation (TAVI).
The objective of this study was to evaluate the timing, predictive factors and prognostic
value of CVE following TAVI.
Methods: A total of 1061 consecutive patients who underwent TAVI with a balloon-
(64%) or a self- (36%) expandable valve in 5 centers were included. CVEs were defined
using the VARC criteria and further classified according to timing with respect to the
TAVI procedure as acute (24 hours), subacute (1 to 30 days), and late (30 days). All
baseline, procedural, and follow-up data were prospectively recorded.
Results: CVEs occurred in 54 patients (5.1%; stroke: 4.2%, TIA: 0.9%) within 30 days
following TAVI, and were acute and subacute in 54% and 46% of cases, respectively. The
predictors of acute CVEs were balloon postdilation (BPD) of the valve prosthesis (OR:
2.46, 95% CI: 1.07-5.67) and valve dislodgment/embolization (OR: 4.36, 95% CI:
1.21-15.69); new-onset atrial fibrillation [NOAF] (OR 2.72, 95% CI 1.10-6.73) was the
only predictor of subactute CVEs. Late CVEs occurred in 35 patients (3.6%; stroke: 2.1%,
TIA: 1.5%) at a median follow-up of 12 (3-23) months. The independent predictors of late
CVEs were chronic AF (HR: 2.62, 95% CI 1.34-5.11) and peripheral vascular disease
(HR: 2.07, 95% CI 1.05-4.08). Major stroke was independently associated with 30-day
(OR 7.43, 95% CI 2.45-22.53) and late (HR: 1.75, 95 CI% 1.01-3.03) mortality.
Conclusions: In a large cohort of patients undergoing TAVI, the rate of acute and
subacute CVEs was 2.7% and 2.4%, respectively. While mechanical factors such as
further stretching of the valve prosthesis with BPD and valve embolization were the
predictors of acute CVEs, atrial arrhythmias (NOAF) determined a higher risk for
subacute events. Late events were mainly determined by chronic AF and peripheral
vascular disease. The occurrence of major stroke was associated with an increased early
and late mortality. These results provide important insights for the implementation of
preventive measures for CVEs following TAVI.
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Background: The predictors of persistent(vs transient or absent)left bundle branch block
(LBBB)after transcatheter aortic valve implantation(TAVI)with a balloon-expandable
valve(BEV)and its clinical consequences are unknown. The aim of this study was to
evaluate the predictors and prognostic value of new-onset persistent LBBB in patients
undergoing TAVI with a BEV.
Methods: A total of 202 consecutive patients with no baseline ventricular conduction
disturbances or previous permanent pacemaker implantation (PPI) who underwent TAVI
with a BEV were included. Patients were on continuous ECG monitoring during
hospitalization and 12-lead ECG was performed daily until hospital discharge. No patient
was lost at a median follow-up of 12 (6-24) months, and ECG tracing was available in
97% of patients. The criteria for PPI were limited to the occurrence of high degree
atrioventricular block (AVB) or severe symptomatic bradycardia.
Results: New-onset LBBB was observed in 61 patients (30.2%) immediately after TAVI,
and had resolved in 37.7% and 57.3 % of them at hospital discharge and at 6 to 12-months
follow-up, respectively. Baseline QRS duration (p0.037) and prosthesis ventricular
depth (p0.017) were independent predictors of persistent LBBB. Persistent LBBB at
hospital discharge was associated with a decrease in left ventricular ejection fraction
(p0.001) and poorer functional status (p0.034) at 1-year follow-up. Patients with
persistent LBBB and no PPI at hospital discharge had a higher incidence of syncope
(16.0% vs. 0.7%, p0.001) and complete AVB requiring PPI (20.0% vs. 0.7%,
p0.001), but not of global mortality, cardiac mortality or sudden death during the
follow-up period (p0.20 for all). New-onset LBBB was the only factor associated with
PPI following TAVI (p0.001).
Conclusions: Up to 30% of the patients with no prior conduction disturbances developed
new LBBB following TAVI with a BEV, although it was transient in more than one third of
them. Longer baseline QRS duration and a more ventricular positioning of the prosthesis were
associated with a higher rate of persistent LBBB, which in turn determined a higher risk for
complete AVB and PPI but not mortality or sudden death at 1-year follow-up.
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Background: A significant perivalvular aortic regurgitation (AR) is observed in 10-20%
after a successful TAVI procedure. The prognostic value and the predictors of such
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